Hi
The journey to bring a new mental health treatment to market is a rigorous one, but the potential of MindBio Therapeutics’ lead candidate, MB22001, makes it all worthwhile. We’re thrilled to share that MB22001 is showing exceptional promise in addressing depression with fewer side effects compared to traditional antidepressants.
Results from our Phase 1 RCTs and Phase 2A depression trials have been remarkable, exceeding expectations as we approach the completion of our Phase 2B trial. We anticipate sharing top-line results from our Depression trial later this year, marking a significant milestone in our mission.
MB22001 has demonstrated substantial improvements in mood, sleep, anxiety, and overall quality of life, with sustained antidepressant effects observed six months after an eight-week treatment cycle. This innovative medicine targets the core symptoms of depression, including low energy, social withdrawal, disrupted sleep, and persistent low mood.
As the most advanced take-home psychedelic medicine in late-stage clinical trials, MB22001’s sub-hallucinogenic microdose allows patients to safely integrate it into their daily lives, much like any other medication, without disruption.
We invite you to join us in championing a brighter future for mental health treatment.
Stay Well!
JUSTIN HANKA
Chief Executive Officer & Co-Founder
MindBio Therapeutics Corp (Frankfurt: WF6), (CNSX: MBIO)
0 comments